177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial

Large, long-term study shows dutasteride reduced prostate cancer risk in men at increased risk of the disease

Experimental Drug Daraxonrasib Shows First Major Survival Benefit for Pancreatic Cancer Patients

An experimental drug called daraxonrasib has become the first treatment to substantially extend the lives of pancreatic cancer patients in a

GE HealthCare and Mayo Clinic launch theranostics study to personalize prostate cancer treatment

GE HealthCare and Mayo Clinic have launched the MI-BET research collaboration, a theranostics study aimed at developing a more personalized

Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial

A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug

Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial

A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug

Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer patients

A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug

Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds

Researchers reported that daraxonrasib, a novel experimental pill, helped patients with advanced pancreatic cancer live longer by blocking a